0
0

Cameron’s Law

2/8/2022, 11:17 PM

Congressional Summary of HR 6238

Cameron's Law

This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit).

The bill also requires the Centers for Disease Control and Prevention to complete a study and report on enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.

Current Status of Bill HR 6238

Bill HR 6238 is currently in the status of Bill Introduced since March 12, 2020. Bill HR 6238 was introduced during Congress 116 and was introduced to the House on March 12, 2020.  Bill HR 6238's most recent activity was Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of March 12, 2020

Bipartisan Support of Bill HR 6238

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 6238

Primary Policy Focus

Taxation

Potential Impact Areas

- Business expenses
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Government studies and investigations
- Income tax credits
- Medical research
- Medical tests and diagnostic methods
- Research and development

Alternate Title(s) of Bill HR 6238

Cameron’s Law
To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit, and for other purposes.
Cameron’s Law

Comments